Highlights
KLSE : NICORP       NAIM INDAH CORPORATION BHD
Last Price Today's Change   Day's Range   Trading Volume
0.12   +0.005 (4.35%)  0.115 - 0.125  4,716,800

Overview

Board:Main Market
Sector:Trading/Services
Avg Volume (4 weeks):7,035,320
4 Weeks Range:0.115 - 0.14
52 Weeks Range:0.10 - 0.145
Average Price Target:0.58
Price Target Upside/Downside:+0.46
View Price Target Detail

Headlines

Latest Headlines
25/11/2014  Nicorp - Unveiling The Truth
30/10/2014  Nicorp - Throttle Forward
19/09/2014  Nicorp - Raging Oils

  12 people like this.
 
limayseng mcm trend akan berubah.....
25/11/2014 12:22
bonescythe Contra player then dun come and spoil it la. U buy n toss.. hurt you and hurt others..
buy what you can hold.. and see the development of the company.

anyhow the insider cost is around 12 cents.. ntg much to lose..
25/11/2014 12:29
getrich so bones today any action ? kekeke
26/11/2014 08:46
ngyl buy can
sell can
c look c look can
don't want c look c look also can
26/11/2014 08:48
yaofong someone set a road block at 0.125
26/11/2014 14:06
flatman wow alot of changes in the boardroom
26/11/2014 20:01
lotusf1 Nice buidings designs n only marred by poor blnced sheet n profits...
27/11/2014 07:56
logitrader http://www.klse.my/financial/quarterResult/YoY/quarter/4464/30-Sep-2014.jsp
27/11/2014 11:36
noorgreen Rto coming..grab at cheap nd hold
27/11/2014 13:32
getrich rights issue and assets transfer sampai sekerang pun tak jalan ... mahu cakap RTO
27/11/2014 14:35


 

264  419  439  582 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 NOVAMSC 0.195-0.01 
 JAG 0.19-0.01 
 DAYA 0.22+0.005 
 SYSTECH 0.310.00 
 SUMATEC 0.265-0.015 
 KNM 0.58-0.01 
 ASIABIO 0.155+0.005 
 SKPETRO 3.09-0.14 
 MEGB 0.79+0.035 
 EFFICEN 0.315-0.025 

TOP ARTICLES

1. [转帖] 人不成熟的五個特徵!!!不成長永遠無法向上爬… Good Articles to Share
2. HOVID - The Medicine to Cure Logic Trading Analysis
3. Market Update - FBM KLCI Semi-Annual Review RHB Research
4. Land & General - Update - savwee Good Articles to Share
5. IFCAMSC wave as of 27/11/2014 - Updated with some pointers. To buy or not to buy, that is the question.
Partners & Brokers